Alzheimer DiseaseNCRADNCT00064870
Alzheimer's Disease Genetics Study
An observational study of Alzheimer Disease and Late Onset Alzheimer Disease, run by Indiana University at 1 site in United States.
Trial summary
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Alzheimer Disease, Late Onset Alzheimer Disease, Dementia
- How many people
- 10,000 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2002to Aug 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Families with two or more members with Alzheimer's disease or dementia
Who may be able to join
- Two living family members diagnosed with AD or other dementia with any age of onset
- Biological samples available
- Fresh blood, or
- Immortalized lymphoblastic cell lines, or
- 3-5 grams of frozen cerebral cortex; fixed samples are not accepted
- Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.
Who cannot join
- Does not meet inclusion criteria
- Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Participants are being recruited from all over the United States
Nationwide, Indiana, 46202
NCRAD Study Coordinator, 800-526-2839, alzstudy@iu.edu
About this study
Official title: National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.
Read the detailed description
The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.
- Conditions
- Alzheimer Disease, Late Onset Alzheimer Disease, Dementia
- Keywords
- Alzheimer disease, Late Onset Alzheimer disease risk factor genes, Genetics, Initiative, Dementia
- Medical subject headings
- Alzheimer Disease, Dementia
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribute biological specimens to qualified investigators for use in their research studies.
Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies.
Measured: Contact investigators annually for an update on progress and publication status.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2003 (estimated)
- Study startJun 2002
- Primary completionAug 2031 (estimated)
- Study completionAug 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Principal investigator, Tatiana Foroud, Indiana University
- Investigators
- Tatiana M. Foroud, PhD, Principal investigator, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00064870
- Sponsor's protocol ID
- IA0042
- Other IDs
- U24AG021886, NIH grant U24 AG21886
- Acronym
- NCRAD
- Status last verified
- Aug 2026
- First submitted
- 14 Jul 2003
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
- ClinicalTrials.gov ID
- NCT00064870
- Acronym / sponsor ID
- NCRAD / IA0042
- Conditions
- Alzheimer Disease, Late Onset Alzheimer Disease, Dementia
- Keywords
- Alzheimer disease, Late Onset Alzheimer disease risk factor genes, Genetics, Initiative, Dementia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- Jun 2002
- Primary completion
- Aug 2031 (estimated)
- Study completion
- Aug 2031 (estimated)
- First posted
- 16 Jul 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.
Detailed description
The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Families with two or more members with Alzheimer's disease or dementia
Key inclusion criteria (6 listed)
- Two living family members diagnosed with AD or other dementia with any age of onset
- Biological samples available
- Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.
Key exclusion criteria (2 listed)
- Does not meet inclusion criteria
- Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Distribute biological specimens to qualified investigators for use in their research studies.
Time frame: Contact investigators annually for an update on progress and publication status.
Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- NCRAD: the National Centralized Repository for Alzheimer's Disease and Related DementiasLink provided by the sponsor.
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Negotiation Training for Family Caregivers of People With Alzheimer's Disease
Alzheimer's Disease (AD), Dementia
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
RecruitingPhase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Alzheimer Disease, Dementia
Not yet recruiting
ALDH2 Genetic Testing in East Asian Community
Healthy Adult, Flushing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tatiana M. Foroud, PhD principal investigator
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer Disease and Late Onset Alzheimer Disease, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Coordinator (1-800-526-2839, alzstudy@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribute biological specimens to qualified investigators for use in their research studies. (time frame: Contact investigators annually for an update on progress and publication status.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.